Myelofibrosis predicts deep molecular response 4.5 in chronic myeloid leukaemia patients initially treated with imatinib: An extensive, multicenter and retrospective study to develop a prognostic model

Tian Zeng , Xiudi Yang , Yi Wang , Dijiong Wu , Weiying Feng , Ying Lu , Xiaoqiong Zhu , Lirong Liu , Mei Zhou , Li Zhang , Yanping Shao , Honglan Qian , Feng Zhu , Yu Chen , Dan Cao , Li Huang , Xiaoning Feng , Lili Chen , Gang Zhang , Jing Le , Weiguo Zhu , Yongming Xia , Yanxia Han , Yongqing Jia , Guoyan Tian , Hui Zhou , Linjuan Xu , Xiufeng Yin , Qinli Tang , Yuefeng Zhang , Guoli Yao , Xianghua Lang , Kaifeng Zhang , Xiujie Zhou , Junbin Guo , Jinming Tu , Jianzhi Zhao , Gongqiang Wu , Huiqi Zhang , Xiao Wu , Qiulian Luo , Lihong Cao , Binbin Chu , Wei Jiang , Haiying Wu , Liansheng Huang , Meiwei Hu , Muqing He , Jingjing Zhu , Hongyan Tong , Jie Jin , Jian Huang

Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (11) : e70101

PDF
Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (11) : e70101 DOI: 10.1002/ctm2.70101
LETTER TO THE JOURNAL

Myelofibrosis predicts deep molecular response 4.5 in chronic myeloid leukaemia patients initially treated with imatinib: An extensive, multicenter and retrospective study to develop a prognostic model

Author information +
History +
PDF

Cite this article

Download citation ▾
Tian Zeng, Xiudi Yang, Yi Wang, Dijiong Wu, Weiying Feng, Ying Lu, Xiaoqiong Zhu, Lirong Liu, Mei Zhou, Li Zhang, Yanping Shao, Honglan Qian, Feng Zhu, Yu Chen, Dan Cao, Li Huang, Xiaoning Feng, Lili Chen, Gang Zhang, Jing Le, Weiguo Zhu, Yongming Xia, Yanxia Han, Yongqing Jia, Guoyan Tian, Hui Zhou, Linjuan Xu, Xiufeng Yin, Qinli Tang, Yuefeng Zhang, Guoli Yao, Xianghua Lang, Kaifeng Zhang, Xiujie Zhou, Junbin Guo, Jinming Tu, Jianzhi Zhao, Gongqiang Wu, Huiqi Zhang, Xiao Wu, Qiulian Luo, Lihong Cao, Binbin Chu, Wei Jiang, Haiying Wu, Liansheng Huang, Meiwei Hu, Muqing He, Jingjing Zhu, Hongyan Tong, Jie Jin, Jian Huang. Myelofibrosis predicts deep molecular response 4.5 in chronic myeloid leukaemia patients initially treated with imatinib: An extensive, multicenter and retrospective study to develop a prognostic model. Clinical and Translational Medicine, 2024, 14(11): e70101 DOI:10.1002/ctm2.70101

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Branford S. Why is it critical to achieve a deep molecular response in chronic myeloid leukemia. Haematologica. 2020;105(12):2730-2737.

[2]

Shanmuganathan N, Hughes TP. Molecular monitoring in CML: how deep? How often? How should it influence therapy. Hematology. 2018;2018(1):168-176.

[3]

García-Gutiérrez V, Breccia M, Jabbour E, Mauro M, Cortes JE. A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase. J Hematol Oncol. 2022;15(1):90.

[4]

Mehmet Sezgin P, Mesut T, Simten D, et al. Prognostic impact of bone marrow fibrosis and effects of tyrosine kinase inhibitors on bone marrow fibrosis in chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2024;24(4).

[5]

Buesche G, Hehlmann R, Hecker H, et al. Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia-prospective long-term results from a randomized-controlled trial. Leukemia. 2003;17(12):2444-2453.

[6]

Buesche G, Ganser A, Schlegelberger B, et al. Marrow fibrosis and its relevance during imatinib treatment of chronic myeloid leukemia. Leukemia. 2007;21(12):2420-2427.

[7]

Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405.

[8]

Branford S, Yeung DT, Ross DM, et al. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood. 2013;121(19):3818-3824.

[9]

de Hond AAH, Shah VB, Kant IMJ, Van Calster B, Steyerberg EW, Hernandez-Boussard T. Perspectives on validation of clinical predictive algorithms. NPJ Digit Med. 2023;6(1):86.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.

AI Summary AI Mindmap
PDF

108

Accesses

0

Citation

Detail

Sections
Recommended

AI思维导图

/